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“Microbial colonization of mammals is
an evolution-driven process that modu-
lates host physiology, many of which are
associated with immunity and nutrient
intake”—Heijtz et al. (2011)
The recognition of the human micro-
biome (HM) as a substantial contribu-
tor to nutrition, health and disease is a
relatively recent one, and currently, peer-
reviewed studies linking alterations in
microbiota to the etiopathology of human
disease are few. Emerging studies indicate
that the HM may contribute to the reg-
ulation of multiple neuro-chemical and
neuro-metabolic pathways through a com-
plex series of highly interactive and sym-
biotic host-microbiome signaling systems
that mechanistically interconnect the gas-
trointestinal (GI) tract, skin, liver, and
other organs with the central nervous sys-
tem (CNS). For example, the human GI
tract, containing 95% of the HM, har-
bors a genetically diverse microbial popu-
lation that plays major roles in nutrition,
digestion, neurotrophism, inflammation,
growth, immunity and protection against
foreign pathogens (Forsythe et al., 2012;
Collins et al., 2013; Douglas-Escobar et al.,
2013; see below). It has been estimated
that about 100 trillion bacteria from up to
1000 distinct bacterial species co-inhabit
the human GI tract, albeit in different sto-
ichiometries amongst individuals, and the
varying combinations and strains of bac-
terial species amongst human populations
might contribute, in part, to “human-
biochemical” or “genetic-individuality”
and resistance to disease (Aziz et al.,
2013; Lukiw, 2013). Interestingly, HM
participation in human physiology may
also help explain the genome-complexity
conundrum—for example why the 26,600
protein-encoding transcripts in Homo
sapiens are far fewer in number, than for
example, the rice genome (Oryza sativa;
which has about 46,000 functional genes).
One thousand different strains of bacte-
ria might be expected to contribute up to
4× 106 potential mRNAs to the human
transcriptome, thus making the human
host-plus-microbiome genetic complex-
ity closer to 4,026,600 mRNA transcripts,
and a clear “winner” of human genetic
complexity over that of rice and other
species (Venter et al., 2001; Foster and
McVey Neufeld, 2013; Lukiw, 2013). The
very recent observation of microbiome-
derived small non-coding RNA (sncRNA)
and micro RNA (miRNA) translocation
and signaling across endothelial barriers,
between cells and tissues, and even per-
haps between individual species indicates
that human neurobiology may be signif-
icantly impacted by the actions of HM-
mediated sncRNA or miRNA trafficking,
and the integration of a cell, tissue or
an entire organism into its local environ-
ment (Zhao et al., 2006; Alexandrov et al.,
2012; Sarkies and Miska, 2013; Reijerkerk
et al., 2013; unpublished). This opinion
paper encompasses what we know con-
cerning the contribution of the HM to
neurological disease, with specific empha-
sis on Alzheimer’s disease (AD) wherever
possible.
Firstly, the microbiome of the human
GI tract is the largest reservoir of microbes
in the body, containing about 1014
microorganisms; over 99% of microbiota
in the gut are anaerobic bacteria, with
fungi, protozoa, archaebacteria and other
microorganismsmaking up the remainder.
There is currently an expanding inter-
est in the ability of intestinal bacteria to
influence neuro-immune functions well
beyond the GI tract. Since mitochondria
are believed to originate from bacteria via
endosymbiotic relationships that formed
very early in the evolutionary history
of eukaryotes, cross-reactivity of mito-
chondria and immunological responses
to intestinal bacterial constituents could
have deleterious effects on mitochondrial
function through some form of molec-
ular mimicry; this is partially evidenced
by the inflammatory basal ganglia disor-
der Sydenham’s chorea, rheumatic fever
and the link to the facultative anaerobe
Streptococcus (Carrasco-Pozo et al., 2012;
Douglas-Escobar et al., 2013; Hayashi,
2013; Hornig, 2013 see below). Established
pathways of GI-CNS communication cur-
rently include the autonomic nervous
system (ANS), the enteric nervous sys-
tem (ENS), the neuroendocrine system,
and the immune system (Camfield et al.,
2011; Heijtz et al., 2011; Forsythe et al.,
2012; Aziz et al., 2013; Collins et al., 2013;
Foster and McVey Neufeld, 2013; Schwartz
and Boles, 2013). Stress further influences
the composition of the HM, and recipro-
cal communication between the CNS and
the HM also influences stress reactivity
(Forsythe et al., 2012; Foster and McVey
Neufeld, 2013). Surprisingly, neuronal sig-
naling pathways along the bidirectional
GI-CNS axis remain poorly understood
despite their important roles: (i) in
coordinating metabolic- and nutritive-
functions, and (ii) in their functional
disruption in chronic diseases such as
metabolic syndrome, diabetes, obesity,
anxiety, autoimmune-disease and stress-
induced neuropsychiatric disease (Lukiw
and Bazan, 2006; Bravo et al., 2012; Foster
and McVey Neufeld, 2013; Hornig, 2013;
Udit and Gautron, 2013). Studies of
the ENS in “germ-free” mice, i.e., those
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missing their microbiome, indicates that
commensal intestinal microbiota are abso-
lutely essential for passive membrane
characteristics, action potentials within
the ENS, and the excitability of sensory
neurons, thus providing a potential mech-
anistic link for the initial exchange of
signaling information between the GI
tract microbiome and the CNS (Foster
and McVey Neufeld, 2013; Hornig, 2013;
McVey Neufeld et al., 2013). Indeed, secre-
tory products of the GI microbiome and
translocation of these signaling molecules
via the lymphatic and systemic circulation
throughout the CNS are just begin-
ning to be identified. For instance, the
GI tract-abundant gram-positive fac-
ultative anaerobic or microaerophilic
Lactobacillus, and other Bifidobacterium
species, are capable of metabolizing glu-
tamate to produce gamma-amino butyric
acid (GABA), the major inhibitory neu-
rotransmitter in the CNS; dysfunctions
in GABA-signaling are linked to anxiety,
depression, defects in synaptogenesis, and
cognitive impairment including AD (Aziz
et al., 2013; Hornig, 2013; Mitew et al.,
2013; Paula-Lima et al., 2013; Saulnier
et al., 2013). To cite another important
example, brain-derived neurotrophic fac-
tor (BDNF) has pleiotropic effects on
neuronal development, differentiation,
synaptogenesis and the synaptic plastic-
ity that underlies circuit formation and
cognitive function, and has been found
to be decreased in brains and serum from
patients with schizophrenia, anxiety and
AD (Carlino et al., 2013; Lu et al., 2013;
Mitew et al., 2013). In experimental infec-
tionmodels known to lead to alterations in
the microbiota profile, BDNF expression
was found to be reduced in the hippocam-
pus and cortex of “germ free” mice, and
this reduction in the expression of BDNF
was found to associate with increased anx-
iety behavior and progressive cognitive
dysfunction (Carlino et al., 2013; Foster
and McVey Neufeld, 2013; Lu et al., 2013).
Equally interesting are microbiome
interactions with the N-methyl-D-
aspartate (NMDA) glutamate recep-
tor, a prominent CNS device that
regulates synaptic plasticity and cog-
nition (Lakhan et al., 2013). For




found elevated in the brains of patients
with amyotrophic-lateral sclerosis (ALS),
Parkinson-dementia (PD) complex of
Guam and AD, has been hypothesized
to be generated by cyanobacteria of the
intestinal microbiome, and stress, GI
tract disease or malnutrition may further
induce BMAA abundance to ultimately
contribute to neurological dysfunction
(Brenner, 2013). Other HM-resident
cyanobacteria-generated neurotoxins such
as saxitoxin and anatoxin-α may further
contribute to human neurological dis-
ease, especially during aging when the
intestinal epithelial barrier of the GI
tract becomes more permeable (Tran
and Greenwood-Van Meerveld, 2013).
Interestingly, BMAA, a neurotoxic amino
acid not normally incorporated into pro-
tein, has been linked with intra-neuronal
protein misfolding, a hallmark feature
of the amyloid peptide-enriched senile
plaque lesions, and resultant inflamma-
tory neurodegeneration, that characterize
PD, AD and prion disease (He and
Balling, 2013; Hornig, 2013; Mulligan
and Chakrabartty, 2013; Schwartz and
Boles, 2013). Hence, besides potentially
altering CNS neurochemistry and neu-
rotransmission, HM-bacteria not only
secrete molecules that potentially mod-
ulate systemic- and CNS-amyloidosis,
they also widely utilize their own amyloid
peptides as structural materials, adhesion
molecules, toxins, molecules that function
in the protection against host defenses and
auto-immunity. The specific contribution
of host bacteria and bacterial amyloid,
however, to misfolding, amyloidogenic
diseases such as AD remain to be more
clearly defined (Schwartz and Boles, 2013).
The HM further appears to condition host
immunity to foreign microbes, includ-
ing viral infection and xenobiotics, while
regulating autoimmune responses that
can impact homeostatic metabolic- and
neural-signaling functions within the
CNS (Ball et al., 2013; Douglas-Escobar
et al., 2013; Hornig, 2013). An increased
prevalence of autoimmunity, exposure
to pathogens both pre- and post-natally,
and findings of anti-brain antibod-
ies, common in disorders as diverse
as anxiety, schizophrenia, obsessive-
compulsive disorder, depression and
autism, together suggest that differences
in exposure and genetic vulnerability
toward HM-mediated autoimmunity may
be significant determinants of age-related
neurological disease course and outcome
(Ball et al., 2013; Douglas-Escobar et al.,
2013; Hornig, 2013).
Regarding potentially pathogenic mico-
biota stationed outside of the GI tract,
about 95% of all humans harbor the highly
neurotrophic herpes simplex-1 (HSV-1)
in their trigeminal ganglia, but whether
this is a neutral or symbiotic rela-
tionship, or detrimental to the host,
remains open to speculation. Induction
of HSV-1, and other forms of endoge-
nous viral reactivation are certainly stress-
related, but whether GI tract HM-derived
metabolites are involved in these kinds
of pathogenic activation mechanisms is
not well understood (Hill et al., 2009;
Prasad et al., 2012). Recent studies sug-
gest that activation of endogenous HSV-
1 or other neurotrophic microorganisms,
including host-embedded prions, are inti-
mately linked to neurological stressors
linked to amyloidogensis, inflammatory
neurodegeneration and progressive cog-
nitive impairment, and may be a con-
tributor to the early development of, or
predisposition to, schizophrenia and AD
(Hill et al., 2009; Prasad et al., 2012; Ball
et al., 2013; Manuelidis, 2013). Indeed,
correlation of metabolic and neurolog-
ical phenotypes with the GI tract HM
and other specific endogenous bacterial
or viral profiles derived from independent
molecular analytical technologies should
be increasingly useful for deciphering
complex host-microbiome relationships in
healthy human brain aging and in neu-
ropsychiatric disease (Xie et al., 2013).
Further studies of symbiotic HM-CNS
communication intrinsically suggests the
potential for microbial-based therapeutic
strategies that may aid in the augmen-
tation of the HM, for the treatment
of human disease, including neurolog-
ical disorders (Forsythe et al., 2012;
Collins et al., 2013). The original obser-
vation of the health-promoting benefits
of GI tract bacteria and the HM was
first introduced in 1907 by the Russian
biologist Ilya Metchnikoff (Nobel Prize
in Medicine 1908, shared with Paul
Erlich; Buryachkovskaya et al., 2013).
Metchnifoff ’s works focused on prokary-
toic immunology, phagocytosis, the
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anti-aging properties instilled by host bac-
teria, inflammation as a protective adap-
tation against injury, and early ideas on
neurogastroenterology (Buryachkovskaya
et al., 2013; Saulnier et al., 2013). Hence,
for well over 100 years, host-beneficial GI
tract bacteria, collectively known as pro-
biotics, have been proposed to be useful
to human health, and more recently have
been added to various foods and diets
because of their positive health-promoting
effects (Singh et al., 2013). The beneficial
actions of bacterial-based probiotics are
highly inter-related, and are thought to
function, in part: (i) to aid in complex
carbohydrate fermentation and absorp-
tion; (ii) to provide a significant source of
a range of essential vitamins, particularly
those of the vitamin B and K group; (iii)
to compete with pathogenic microorgan-
isms in the GI tract; (iv) to antagonize
and neutralize enteric pathogens; (v) to
metabolize and neutralize dietary carcino-
gens; and (vi) to favorably modulate the
host’s immune response to resist infec-
tion and disease. Besides the potential
application of probiotics in the prevention
and treatment of various health condi-
tions and diseases such as allergies, GI and
urogenital tract infections, inflammatory
disease, cystic-fibrosis and certain can-
cers there is increasing interest of positive
microbiome effects toward the CNS via
neural, neuroendocrine, neuroimmune
and humoral links (Duncan and Flint,
2013; He and Balling, 2013; Saulnier et al.,
2013). For example, there is preliminary
research on the influence of probiotics
and nutritional factors on the prognosis
of multiple sclerosis (von Geldern and
Mowry, 2012), cognition (Camfield et al.,
2011), neurogastroenterology in general
(Saulnier et al., 2013), and stress-related
psychiatric conditions including anxiety,
autism, depression and schizophrenia
(Bravo et al., 2012; Prasad et al., 2012;
Douglas-Escobar et al., 2013). Advances
in probiotic technologies in CNS disease
research are already raising a number of
ethical, legal, and socioeconomic concerns
(Slashinski et al., 2012).
Lastly, the US NIH “Roadmap” pro-
gram has recently initiated the HM project
(HMP; http://commonfund.nih.gov/
technologies with the specific aims (i) to
characterize the microbial communities at
several different sites on the human body,
including nasal, oral and otic cavities,
the skin, GI and urogenital tracts; (ii)
to analyze the role of these microbes in
homeostatic human physiology; (iii) to
catalog specific microbiome speciation,
composition and correlation with disease;
and (iv) to generate resources enabling
comprehensive characterization of the
HM by multiple independent research
groups. These investigations present a
highly significant and exciting avenue for
future study, and suggest new and perhaps
unconventional directions for AD research
in 2013 and beyond. Future AD thera-
pies may well, in part, involve probiotic
approaches, especially as a prophylactic
tactic before mild-cognitive impairment
(MCI) or AD is first diagnosed. The impli-
cations of altered host-HM interactions
in neurological disease would be far-
reaching indeed, and these may engender
novel microbiome manipulative strategies,
tailored to the host, for the more effec-
tive therapeutic management of AD and
related neuropsychiatric disorders.
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